Neurohumoral mechanisms involved in congestive heart failure.
暂无分享,去创建一个
[1] J. Cohn,et al. Neurohumoral control mechanisms in congestive heart failure. , 1981, American heart journal.
[2] L. I. Goldberg,et al. A comparison of the vascular dopamine receptor with other dopamine receptors. , 1978, Annual review of pharmacology and toxicology.
[3] A. A. Taylor,et al. Propylbutyldopamine: Hemodynamic Effects in Conscious Dogs, Normal Human Volunteers and Patients with Heart Failure , 1983, Circulation.
[4] W. Feldberg,et al. The action of peptides on the adrenal medulla. Release of adrenaline by bradykinin and angiotensin , 1964, The Journal of physiology.
[5] J. Cohn,et al. The Neurohumoral and Hemodynamic Response to Orthostatic Tilt in Patients with Congestive Heart Failure , 1983, Circulation.
[6] F. Abboud,et al. Sensitization of cardiac receptors (vagal afferents) by intracoronary acetylstrophanthidin. , 1980, The American journal of physiology.
[7] Cowley Aw,et al. Role of vasopressin in cardiovascular regulation. , 1983 .
[8] R. Nadeau,et al. Regulation of norepinephrine release from cardiac sympathetic fibers in the dog by presynaptic alpha- and beta-receptors. , 1977, Circulation research.
[9] M. Manning,et al. Design and uses of selective agonistic and antagonistic analogs of the neuropeptides oxytocin and vasopressin , 1984, Trends in Neurosciences.
[10] S. Z. Langer,et al. Recent developments in vascular smooth muscle pharmacology: the post-synaptic α2-adrenoceptor , 1982 .
[11] J. Federman,et al. Oral beta-adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy. , 1984, Journal of the American College of Cardiology.
[12] J. Laragh,et al. Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients. , 1976, The American journal of medicine.
[13] D. Jacobowitz,et al. Increased dopamine in the failing hamster heart: transvesicular transport of dopamine limits the rate of norepinephrine synthesis. , 1982, The American journal of cardiology.
[14] R. Gorlin,et al. Hemodynamic and Clinical Tachyphylaxisc to Prazosin-Mediated Afterload Reductionin Severe Chronic Congestive Heart Failure , 1979, Circulation.
[15] J. Cohn,et al. The neurohumoral axis in congestive heart failure. , 1984, Annals of internal medicine.
[16] S. Z. Langer. Presynaptic regulation of the release of catecholamines. , 1980, Pharmacological reviews.
[17] A. Sjoerdsma,et al. ELUCIDATION OF THE RATE-LIMITING STEP IN NOREPINEPHRINE BIOSYNTHESIS IN THE PERFUSED GUINEA-PIG HEART. , 1965, The Journal of pharmacology and experimental therapeutics.
[18] G. Ross. Adrenergic responses of the coronary vessels. , 1976, Circulation research.
[19] Y. Yamane. Plasma ADH level in patients with chronic congestive heart failure. , 1968, Japanese circulation journal.
[20] L. Share. Interrelations between vasopressin and the renin-angiotensin system. , 1979, Federation proceedings.
[21] J. Cohn,et al. The effects of bromocriptine in patients with congestive heart failure. , 1983, American heart journal.
[22] D. Harrison,et al. Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. , 1983, American heart journal.
[23] R. Roth,et al. Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation , 1971, British journal of pharmacology.
[24] E. Braunwald,et al. CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE. , 1965, The American journal of medicine.
[25] D. Goldstein,et al. Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology. , 1981, The American journal of cardiology.
[26] K. Malik. Prostaglandins--modulation of adrenergic nervous system. , 1978, Federation proceedings.
[27] P. A. Zwieten,et al. Cardiovascular α2-receptors , 1983 .
[28] R. Moulds,et al. Facilitatory prejunctional β-adrenoceptors in human arteries and veins , 1983 .
[29] L. Toll,et al. Role of Mg2+-ATPase and a pH gradient in the storage of catecholamines in synaptic vesicles. , 1978, Biochemistry.
[30] S. Udenfriend,et al. TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS. , 1964, The Journal of biological chemistry.
[31] R. Roth,et al. Angiotensin accelerates Catecholamine Biosynthesis in Sympathetically Innervated Tissues , 1969, Nature.
[32] T. Nicholas. Potentiation of the effects of noradrenaline and of sympathetic stimulation of the perfused rat caudal artery by angiotensin , 1970, The Journal of pharmacy and pharmacology.
[33] J. Cohn,et al. Increased plasma arginine vasopressin levels in patients with congestive heart failure. , 1983, Journal of the American College of Cardiology.
[34] J. Laragh. Hormones and the Pathogenesis of Congestive Heart Failure: Vasopressin, Aldosterone, and Angiotensin II Further Evidence for Renal‐Adrenal Interaction from Studies in Hypertension and in Cirrhosis , 1962, Circulation.
[35] R. Arbogast,et al. Greatly Enhanced Pressor Response to Antidiuretic Hormone in Patients with Impaired Cardiovascular Reflexes Due to Idiopathic Orthostatic Hypotension , 1980, Journal of cardiovascular pharmacology.
[36] M. Sole,et al. Effects of bromocriptine on plasma catecholamines in normal men. , 1979, Neuroendocrinology.
[37] D C Harrison,et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.
[38] P. Khairallah,et al. Inhibition of noradrenaline uptake by angiotensin , 1967, The Journal of pharmacy and pharmacology.
[39] Zimmerman Bg. Actions of angiotensin on adrenergic nerve endings. , 1978 .
[40] S. Z. Langer. SIXTH GADDUM MEMORIAL LECTURE NATIONAL INSTITUTE FOR MEDICAL RESEARCH, MILL HILL, JANUARY 1977 , 1977, British journal of pharmacology.
[41] S. Z. Langer,et al. POSSIBLE ROLE OF A β‐ADRENOCEPTOR IN THE REGULATION OF NORADRENALINE RELEASE BY NERVE STIMULATION THROUGH A POSITIVE FEED‐BACK MECHANISM , 1975, British journal of pharmacology.
[42] S. Oparil,et al. Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat. , 1984, The Journal of pharmacology and experimental therapeutics.
[43] T. Slotkin,et al. SYNAPTIC VESICLES ISOLATED FROM RAT HEART: l‐[3H]NOREPINEPHRINE UPTAKE PROPERTIES 1 , 1979, Journal of neurochemistry.
[44] R McCarty,et al. Relationship between plasma norepinephrine and sympathetic neural activity. , 1983, Hypertension.
[45] G. Ross,et al. Effects of a cardio-selective beta-adrenergic blocking agent on the heart and coronary circulation. , 1970, Cardiovascular research.
[46] J. Cohn,et al. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. , 1982, The American journal of cardiology.
[47] S. Langer,et al. PRESYNAPTIC RECEPTORS AND THEIR ROLE IN THE REGULATION OF TRANSMITTER RELEASE. , 1977 .
[48] M. Fregly,et al. Effect of in vitro administration of captopril on vascular reactivity of rat aorta. , 1982, Hypertension.
[49] J. Montani,et al. Hemodynamic Effects of Exogenous and Endogenous Vasopressin at Low Plasma Concentrations in Conscious Dogs , 1980, Circulation research.
[50] D L Eckberg,et al. Defective cardiac parasympathetic control in patients with heart disease. , 1971, The New England journal of medicine.
[51] H. Sarau,et al. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. , 1982, The Journal of pharmacology and experimental therapeutics.
[52] J. T. Shepherd,et al. Metabolic modulation of neurotransmitter release--adenosine, adenine nucleotides, potassium, hyperosmolarity, and hydrogen ion. , 1978, Federation proceedings.
[53] J. Shiloach,et al. The evolutionary origins of hormones, neurotransmitters, and other extracellular chemical messengers: implications for mammalian biology. , 1982, The New England journal of medicine.
[54] M. Sole,et al. A possible change in the rate-limiting step for cardiac norepinephrine synthesis in the cardiomyopathic Syrian hamster. , 1977, Circulation research.
[55] I. Shoulson,et al. Bromocriptine inhibits norepinephrine release , 1979, Clinical pharmacology and therapeutics.
[56] M. Karmazyn,et al. Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins. , 1978, Endocrinology.
[57] E. Sharpey-Schafer,et al. Effects of Valsalva's Manœuvre on the Normal and Failing Circulation , 1955, British medical journal.
[58] L. I. Goldberg,et al. Peripheral dopamine receptors: A classification based on potency series and specific antagonism , 1983 .
[59] J. A. Thomas,et al. Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.
[60] J. Cohn,et al. Elevated left ventricular myocardial dopamine in preterminal idiopathic dilated cardiomyopathy. , 1983, The American journal of cardiology.